Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs
- PMID: 1309849
- DOI: 10.1093/infdis/165.2.376
Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs
Abstract
The nu/nu mouse xenograft is the only experimental system permitting the growth of human papillomaviruses (HPV). Previous studies demonstrating inhibition of HPV-11 infection by antibodies against HPV-11 virions have used indirect markers of infection, such as graft size and histopathologic features. The presence of HPV-11 mRNAs was used as a direct marker of infection: Infectious HPV-11 was incubated with rabbit serum raised against purified HPV-11 virions or with the corresponding preimmune serum (controls) before use in the mouse xenograft model, and HPV-11 mRNAs were detected by a method using reverse transcription and amplification by polymerase chain reaction. Graft size, histopathologic features, and the presence of capsid antigen were also assessed. Six weeks after infection, 1 of 23 grafts in the test group contained HPV-11 mRNAs compared with 19 of 20 controls (P less than .001). Therefore, antibody-mediated inhibition of infection by HPV-11 leads to blockade of genomic expression and is thus consistent with active prevention of viral penetration, that is, neutralization.
Similar articles
-
Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.J Med Virol. 1997 Nov;53(3):185-8. doi: 10.1002/(sici)1096-9071(199711)53:3<185::aid-jmv1>3.0.co;2-4. J Med Virol. 1997. PMID: 9365880
-
Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera.J Gen Virol. 1994 Aug;75 ( Pt 8):2075-9. doi: 10.1099/0022-1317-75-8-2075. J Gen Virol. 1994. PMID: 8046412
-
Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro.J Invest Dermatol. 1995 Sep;105(3):438-44. doi: 10.1111/1523-1747.ep12321173. J Invest Dermatol. 1995. PMID: 7665926
-
Characterization of the humoral immune response to genital papillomaviruses.Mol Biol Med. 1990 Feb;7(1):59-72. Mol Biol Med. 1990. PMID: 2157937 Review.
-
Serological assays for the detection of HPV antibodies.IARC Sci Publ. 1992;(119):147-61. IARC Sci Publ. 1992. PMID: 1330907 Review.
Cited by
-
In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.J Virol. 1998 Feb;72(2):959-64. doi: 10.1128/JVI.72.2.959-964.1998. J Virol. 1998. PMID: 9444988 Free PMC article.
-
How will HPV vaccines affect cervical cancer?Nat Rev Cancer. 2006 Oct;6(10):753-63. doi: 10.1038/nrc1973. Nat Rev Cancer. 2006. PMID: 16990853 Free PMC article. Review.
-
Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin.J Virol. 1993 Dec;67(12):7131-9. doi: 10.1128/JVI.67.12.7131-7139.1993. J Virol. 1993. PMID: 8230435 Free PMC article.
-
Oral immunogenicity of human papillomavirus-like particles expressed in potato.J Virol. 2003 Aug;77(16):8702-11. doi: 10.1128/jvi.77.16.8702-8711.2003. J Virol. 2003. PMID: 12885889 Free PMC article.
-
Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly.J Virol. 1997 Apr;71(4):2988-95. doi: 10.1128/JVI.71.4.2988-2995.1997. J Virol. 1997. PMID: 9060658 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials